TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19965822
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) plus low fluence photodynamic therapy (PDT)
Study: 16062094
Drug: Fluphenazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine (12.5 mg/day)
Study: 11853004
Drug: Irinotecan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 120 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1
Study: 11853004
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1
Study: 3109060
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (5000 IU twice daily)
Study: 26552503
Drug: Thienopyridine (prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine (prasugrel 60 mg or clopidogrel 600 mg)
Study: 25060833
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment program (MTP)
Study: 25060833
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care (treatment-as-usual, TAU)
Study: 18353909
Drug: Multilevel school-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel school-based intervention; specific details on dosage and duration not available.
Study: 18713888
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 3 microg/mL
Study: 18713888
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 4.5 microg/mL
Study: 18713888
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 6 microg/mL
Study: 10080585
Drug: 8 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 months of chemotherapy with irradiation (XRT) of the primary site; 7 patients
Study: 10080585
Drug: 8 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 months of chemotherapy without XRT; 4 patients
Study: 10080585
Drug: 9 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 weeks of chemotherapy without XRT; 20 patients
Study: 6130329
Drug: Epoprostenol (prostacyclin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol (prostacyclin, PGI2) infusion at 7.5 ng/kg/min after the first hour for 5 hours, administered weekly for three weeks.
Study: 6130329
Drug: Buffer infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer infusion (control group) for 5 hours, administered weekly for three weeks.
Study: 6130329
Drug: Epoprostenol (prostacyclin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol (prostacyclin, PGI2) infusion.
Study: 31141195
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of antiretroviral treatment (ART) within 14 days
Study: 31141195
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of antiretroviral treatment (ART) after nutritional recovery
Study: 24786016
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous (SC) injection of 12.5 mg rhTNFR-Fc
Study: 24786016
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous (SC) injection of 25 mg rhTNFR-Fc
Study: 24786016
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous (SC) injection of 50 mg rhTNFR-Fc
Study: 24786016
Drug: Six SC
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six SC injections of 25 mg rhTNFR-Fc once every 3 days
Study: 23006933
Drug: Sericin cream
Normalized name: sericin 1
DrugBank: Silk sericin (DB15531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sericin cream
Study: 23006933
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base (placebo)
Study: 20329659
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (test formulation, 250 mg/5 mL suspension)
Study: 20329659
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of cefuroxime axetil
Study: 11899906
Drug: Various dose-fractionation
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dose-fractionation schedules for palliative radiotherapy
Study: 8553306
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg/day for 15 days and then tapering off)
Study: 92589
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with lipocaine or trimecaine (antiarrhythmic drugs)
Study: 30510079
Drug: Ravulizumab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (900 mg every 8 weeks)
Study: 30510079
Drug: Eculizumab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (900 mg every 2 weeks)
Study: 28433518
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20 mL
Study: 17045903
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus training in physical counterpressure maneuvers (PCM)
Study: 17045903
Drug: Standardized conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized conventional therapy alone
Study: 15613917
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg aspartame (control test)
Study: 10775738
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg oral micronized 17beta‐E2
Study: 10775738
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral micronized 17beta‐E2
Study: 10775738
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral micronized 17beta‐E2
Study: 10775738
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral micronized 17beta‐E2
Study: 9369050
Drug: Midazolam 3
Normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3 mg i.m.
Study: 9369050
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg orally
Study: 9369050
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Atropine 0.5 mg i.m.)
Study: 9369050
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg i.m.
Study: 3755561
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 0.5% hyperbaric tetracaine
Study: 3755561
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 0.5% hyperbaric bupivacaine
Study: 29864467
Drug: 40% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% hydrogen peroxide topical solution (HP40)
Study: 22789134
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of pumactant
Study: 16607924
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 1 year
Study: 15756212
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 1 year followed by a second year of GH
Study: 10500313
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg/q12hr)
Study: 10500313
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (target aPTT: 55‐85 sec)
Study: 1825737
Drug: Ketoconazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (600 mg/day)
Study: 22926599
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 0.5 mg/kg per day for 1 week, followed by 1.2 mg/kg per day for 7 weeks
Study: 16860259
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Pioglitazone (MET + PIO)
Study: 15113713
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (2.8 g DHA/d)
Study: 11355946
Drug: Standard-dose FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FEC (5 adjuvant courses of 5-FU, epirubicin, and cyclophosphamide)
Study: 11355946
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with PBSCT (4 x FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin, and autologous PBSCT)
Study: 11355946
Drug: Both standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both standard-dose and high-dose chemotherapy
Study: 11355946
Drug: Individual patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual patients post-treatment
Study: 8172356
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with a purified standardized preparation of Dermatophagoides farinae for 12 months
Study: 2971185
Drug: RU 41740
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 41740 (two tablets per day for one week during the first month and one tablet per day for one week during the second and third months)
Study: 16516598
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for heart failure
Study: 15281476
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (Pulmicort Respules)
Study: 15281476
Drug: Reference treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatments
Study: 16179595
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg)
Study: 9818697
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Study: 9818697
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Study: 2527239
Drug: Farlutal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farlutal (500 mg MPA tablets, twice daily for 20 days)
Study: 2527239
Drug: Clinovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinovir (500 mg MPA tablets, twice daily for 20 days)
Study: 4624595
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate administered 20 minutes before exercise
Study: 4624595
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate administered immediately before exercise
Study: 4624595
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate administered at the end of exercise
Study: 25928870
Drug: Nonspecific biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific biofeedback treatment
Study: 24298764
Drug: Bloodletting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bloodletting therapy at Jing‐well points
Study: 24298764
Drug: Semen coicis
Normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semen coicis preparation
Study: 24298764
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (bloodletting therapy and semen coicis preparation)
Study: 16685008
Drug: Albuterol pretreatment
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol pretreatment
Study: 14993633
Drug: ROM (rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROM (rifampin 600 mg, ofloxacin 400 mg, minocycline 100 mg)
Study: 14993633
Drug: MDT (rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT (rifampin 600 mg, clofazimine 300 mg, dapsone 100 mg, clofazimine 50 mg)
Study: 11485587
Drug: Anti-tubercular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tubercular treatment
Study: 30484757
Drug: Maternal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal protein intake in early pregnancy (g/d per kg)
Study: 30484757
Drug: Maternal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal protein intake from 6 months to 5 years (g/d per kg)
Study: 28806537
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration (2000 ml of water)
Study: 28806537
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no more than 100 ml of water)
Study: 21441125
Drug: Qa <650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qa <650 ml/min in distal fistulae
Study: 21441125
Drug: Positive PE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive PE and Qa <900 ml/min in proximal fistulae
Study: 18568520
Drug: N(2)O inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(2)O inhalation (10 breaths of 50% N(2)O/50% O(2))
Study: 12975669
Drug: gemcitabine/5‐fluorouracil (5FU)/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine/5‐fluorouracil (5FU)/leucovorin combination
Study: 11094000
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of isobaric bupivacaine (0.2%)
Study: 11094000
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of isobaric ropivacaine (0.3%)
Study: 1595337
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine in combination with rectally administered naproxen 1000 mg/24 h
Study: 1595337
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine in combination with paracetamol 4000 mg/24 h
Study: 1595337
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine as a sole agent
Study: 31464192
Drug: Receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of weekly recommendations
Study: 31464192
Drug: Coached treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coached treatment
Study: 23917458
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administered in 2 doses (1 hour preoperatively and 6 hours postoperatively)
Study: 22464576
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (aspirin + low molecular weight heparin)
Study: 22464576
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conventional treatment and clopidogrel
Study: 18327838
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents for inducing hyperaemia during coronary physiology studies
Study: 15899049
Drug: Risedronate 15
Normalized name: risedronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 15 mg
Study: 15899049
Drug: Risedronate (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (both doses)
Study: 3749616
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of salbutamol and beclomethasone dipropionate from a combination inhaler
Study: 3749616
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of salbutamol and beclomethasone dipropionate from separate inhalers with an interval of 10 min
Study: 29268667
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus regular visits from a therapy dog
Study: 23989837
Drug: Resin infiltration
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin infiltration treatment for WSLs
Study: 18507832
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and Omeprazole (OA)
Study: 18507832
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with OA and CLR (OAC)
Study: 17073704
Drug: Prostanoids (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostanoids (e.g., PGE(1)) used for treatment of peripheral arterial disease
Study: 14621749
Drug: Vasodilator drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator drugs during organ procurement
Study: 26564102
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 mL/d) for 21 days
Study: 20508185
Drug: Recreational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational therapy (playing cards, bingo, or 'Jenga')
Study: 16873669
Drug: R-CHOP induction
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP induction (R: 375 mg/m² intravenously, day 1)
Study: 16873669
Drug: R maintenance
Normalized name: urinary catheter maintenance solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: R maintenance (375 mg/m² intravenously once every 3 months for a maximum of 2 years)
Study: 14608138
Drug: In-hospital initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In-hospital initiation of cardiovascular protective medications (including antiplatelet therapy, beta-blockers, ACE inhibitors, and lipid-lowering therapy)
Study: 1634926
Drug: Thiotepa (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa (75 mg/m2) + GM-CSF (10 micrograms/kg)
Study: 1634926
Drug: Thiotepa (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa (75 mg/m2) + GM-CSF (5 micrograms/kg)
Study: 1634926
Drug: Thiotepa (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa (75 mg/m2) + GM-CSF (10 or 5 micrograms/kg)
Study: 25370364
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy for Obesity (CRT‐O)
Study: 12740277
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (no BPS)
Study: 3468598
Drug: Effervescent vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent vitamin C preparations
Study: 3468598
Drug: Effervescent calcium
Normalized name: Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent calcium preparations
Study: 3468598
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C preparations (excess consumption)
Study: 29943185
Drug: Immediate post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate post-treatment non-perfused volume (NPV)
Study: 21747837
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate (10 mg/kg/day for 45 days)
Study: 21747837
Drug: Systemic meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days)
Study: 17250728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirtazapine 4.5 mg and ibuprofen 400 mg
Study: 17250728
Drug: Mirtazapine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 4.5 mg
Study: 15899956
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment 25.0 microg/kg.d
Study: 15899956
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment 12.5 microg/kg.d
Study: 10321443
Drug: Indapamide 1.25
Normalized name: indapamide 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.25 mg daily
Study: 10321443
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of indapamide and low-salt diet
Study: 2197755
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment for hyperlipidemia
Study: 2197755
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for hyperlipidemia
Study: 2197755
Drug: Combined therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapies for hyperlipidemia
Study: 403549
Drug: Marijuana (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana (500 mg cigarette containing 2.1% delta9-THC)
Study: 31702120
Drug: ACBMNC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACBMNC infusion (5 × 10^7 cells/kg)
Study: 24069775
Drug: Shortened postpartum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shortened postpartum course of magnesium sulphate (two doses of intramuscular magnesium sulphate given four hours apart)